Evidence map›Paper›PMID 29522117›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2018

ESR1 and endocrine therapy resistance: more than just mutations.

S Piscuoglio, C K Y Ng, B Weigelt, S Chandarlapaty, J S Reis-Filho

Abstract readEditorialComment

In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it

0cells of the map it votes in

5citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

Cancers · 2023
Review
m6A readers, writers, erasers, and the m6A epitranscriptome in breast cancer.Journal of molecular endocrinology · 2023
Review
FoxO3a Inhibits Tamoxifen-Resistant Breast Cancer Progression by Inducing Integrin α5 Expression.Cancers · 2022
Article
ERBB2 as a prognostic biomarker correlates with immune infiltrates in papillary thyroid cancer.Frontiers in genetics · 2022
Article
Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?International journal of molecular sciences · 2021
Review

4 · The record

Corrections and comments

Comment on
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.2018

5 · Who and what money

Authors and funding

5 authors.

S PiscuoglioInstitute of Pathology and Medical Genetics, University Hospital Basel, Basel, Switzerland.

C K Y NgInstitute of Pathology and Medical Genetics, University Hospital Basel, Basel, Switzerland; Department of Biomedicine, University of Basel, Basel, Switzerland.

B WeigeltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.

S ChandarlapatyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA.

J S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: reisfilj@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026

$347.4M

NCI NIH HHS P30 CA008748

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsBreastEstrogen Receptor alphaHumansMutationTamoxifenEstrogen Receptor alphaTamoxifen

Identifiers

PMID29522117

DOI10.1093/annonc/mdy081

PMCPMC5913621

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.